Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test With MilliporeSigma, Hamilton Company

Oct 29, 2020

|

NEW YORK – Mammoth Biosciences said on Thursday that it has signed agreements with MilliporeSigma and Hamilton Company to commercialize a high-throughput, CRISPR-based SARS CoV-2 test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test With MilliporeSigma, Hamilton Company

To read the full story....

Breaking News

Somalogic Closes $121M Series A Funding

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

In Brief This Week: Quest Diagnostics, Fluidigm, BD, and More

Tempus Gets CE Mark for xT Tumor Sequencing Assay

BTIG Downgrades Fulgent Genetics from Buy to Neutral

What's Popular?

BTIG Downgrades Fulgent Genetics from Buy to Neutral

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Quest Diagnostics Enters Lab Services Agreement With Montefiore Nyack, Goshen Hospital

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

Agilent Q4 Revenues Rise 8 Percent

Sponsorships